BioNTech SE

Total Valuation

BioNTech SE carries a market capitalization of 20.46B, placing it among publicly traded companies globally. Its enterprise value stands at 4.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioNTech SE currently has 252.88M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 6.62, and the price-to-book ratio stands at 1.05.

Enterprise Valuation

On an enterprise value basis, BioNTech SE trades at an EV/EBITDA multiple of 22.68 and an EV/FCF ratio of 4.09. The EV/Sales ratio of 1.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.46 provides insight into valuation relative to core operating earnings.

Financial Position

BioNTech SE maintains a current ratio of 8.80, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.62, indicating elevated leverage, while an interest coverage ratio of -42.57 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, BioNTech SE has paid 78.70M in income taxes, reflecting an effective tax rate of 216.19.

Stock Price Statistics

BioNTech SE's stock has declined approximately -13.56838% over the past 52 weeks. The 50-day moving average sits at 79.81, while the 200-day moving average is 85.05.

Income Statement

Over the trailing twelve months, BioNTech SE generated 2.81B in revenue and converted that into -1.25B in net income, yielding earnings per share of -5.12. EBITDA reached -315.00M, while operating income came in at -776.30M.

Balance Sheet

BioNTech SE holds 14.64B in cash and equivalents against 302.80M in total debt, resulting in a net debt position of -9.86B. Total book value stands at 17.69B, with working capital of 13.77B providing operational flexibility.

Cash Flow

BioNTech SE produced 815.70M in operating cash flow over the past twelve months. After subtracting -209.80M in capital expenditures, free cash flow totaled 605.90M - equivalent to 2.48 per share.

Margins

BioNTech SE operates with a gross margin of 77.56, reflecting its pricing power and cost economics. The operating margin of -27.67 and net profit margin of -44.64 provide insight into operational efficiency.

Dividends & Yields

Scores

BioNTech SE posts an Altman Z-Score of 6.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.